Recently, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. obtained the "high-tech enterprise certificate" jointly issued by Shanghai Municipal Commission of Science and Technology, Shanghai Municipal Bureau of Finance and Shanghai Municipal Bureau of Taxation of the State Administration of Taxation.

According to the national conditions for the identification of high-tech enterprises, enterprises must comprehensively meet the requirements in eight aspects, including core intellectual property rights, scientific and technological research and innovation capabilities, high-tech product transformation capabilities, growth indicators and talent structure, in order to obtain certification. The acquisition of this high-tech enterprise certificate is an authoritative affirmation of the technological strength and R&D level of Loqi.

In the future, as a high-tech enterprise, Loki Biology will continue to adhere to the spirit of active innovation and forge ahead, continue to increase investment in research and development, continue to improve technological innovation capacity, and make contributions to human health.

About novamab

Luoqi Biology is a high-tech enterprise dedicated to the research and development of innovative nano antibody drugs. The company was established in Shanghai International Medical Park, with a R&D and production base of more than 1600 square meters and a unique camel breeding base. Luoqi Biological has independently created five core technology platforms based on nano-antibody: nano-antibody rapid screening platform, Pichia pastoris CMC process development platform, inhaled macromolecular drug research and development platform, nano-antibody long-acting platform and nano-antibody dual-antibody platform, all of which have very unique industry advantages. At present, the company is mainly developing products to cover popular targets such as respiration, ophthalmology and cancer, and has developed product research and development strategies for innovative application scenarios to improve drug utilization and patient compliance.